Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276), a pharmaceutical heavyweight based in China, has received approval from the National Medical Products Administration (NMPA) to commence clinical studies on its innovative drug candidates. The study will explore the synergistic effects of HRS-6209 in combination with HRS-1358, HRS-8080, or aromatase inhibitors, and fulvestrant for the treatment of breast cancer. This marks a significant stride in the company’s pipeline development.
HRS-1358, an estrogen receptor (ER)-targeted PROTACT molecule developed in-house, is designed to inhibit tumor cell proliferation and overcomes mutation resistance with higher selectivity than traditional small-molecule drugs. HRS-8080, a selective oral ER degrading agent, is poised to address ER positive and ER mutant breast cancer. HRS-6209, a selective cell cycle blocker, induces G0/G1 phase arrest in tumor cells, exerting an anti-tumor effect. The global market has not yet seen similar products, indicating the potential for Hengrui’s offerings to fill significant therapeutic gaps.- Flcube.com
